GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (LTS:0OCQ) » Definitions » Total Long-Term Liabilities

Transgene (LTS:0OCQ) Total Long-Term Liabilities : €12.99 Mil (As of Dec. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Transgene Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Transgene's Total Long-Term Liabilities for the quarter that ended in Dec. 2024 was €12.99 Mil.

Transgene Total Long-Term Liabilities Historical Data

The historical data trend for Transgene's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transgene Total Long-Term Liabilities Chart

Transgene Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.11 20.04 15.81 19.56 12.99

Transgene Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.81 15.07 19.56 39.19 12.99

Transgene Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Transgene Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Transgene's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Transgene Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (LTS:0OCQ) » Definitions » Total Long-Term Liabilities
Comparable Companies
XPAR:MAAT XPAR:ALSEN XPAR:ADOC XPAR:ALGAE XPAR:ABNX XPAR:ALGEN XPAR:OSE XPAR:SIGHT XPAR:POXEL XPAR:ALDVI VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
TRGNF:USA TNG:France TGNA:Germany
Address
400, Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, Strasbourg, FRA, 67400
Website
https://www.transgene.fr
Transgene SA is a biotechnology company that designs and develops targeted immunotherapy products for cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The company's portfolio of products in clinical development includes TG4050, an individualized therapeutic vaccine based on the myvac platform, TG4001, a therapeutic vaccine for HPV positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Geographically, the majority of its operations are located in France.

Transgene Headlines

No Headlines